Laquinimod

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is currently being investigated for its potential use in treating multiple sclerosis and Huntington's disease.

Mechanism of Action[edit | edit source]

Laquinimod is believed to work by modulating the immune system, reducing inflammation and potentially even promoting neuroprotection. However, the exact mechanism of action is not fully understood.

Clinical Trials[edit | edit source]

Laquinimod has undergone several clinical trials to assess its safety and efficacy in treating multiple sclerosis and Huntington's disease.

Multiple Sclerosis[edit | edit source]

In clinical trials for multiple sclerosis, laquinimod has shown a reduction in the rate of relapse and a slowing of disease progression. However, it has not yet been approved for use in this condition.

Huntington's Disease[edit | edit source]

Clinical trials for Huntington's disease are ongoing. Preliminary results suggest that laquinimod may slow the progression of the disease, but further research is needed.

Side Effects[edit | edit source]

Common side effects of laquinimod include back pain, cough, and diarrhea. More serious side effects may include liver damage and severe allergic reactions.

See Also[edit | edit source]

Laquinimod Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.